Make your own free website on Tripod.com

Primary/Progressive Multiple Sclerosis 3

  1. Normal-Appearing Brain T1 relaxation time predicts disability in early Primary/Progressive Multiple Sclerosis
    Arch Neurol 2007 Mar;64(3):411-5

  2. Gray Matter damage predicts the evolution of Primary/Progressive Multiple Sclerosis at 5 years
    Brain 2006 Oct;129(Pt 10):2628-34

  3. Is inflammation important in early PPMS? a longitudinal MRI study
    J Neurol NeuroSurg Psychiatry 2005 Sep;76(9):1255-8

  1. Primary/Progressive Multiple Sclerosis: clinical and paraclinical characteristics with application of the new diagnostic criteria
    Eur J Neurol 2004 Jul;11(7):439-44

  2. Magnetic Resonance Imaging predictors of disability in Primary/Progressive Multiple Sclerosis: a 5-year study
    Mult Scler 2004 Aug;10(4):398-401

  3. Overview of Primary/Progressive Multiple Sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis
    Mult Scler 2004 Jun;10 Suppl 1:S2-7

  4. Natural history of Primary/Progressive Multiple Sclerosis
    Mult Scler 2004 Jun;10 Suppl 1:S8-13; discussion S13-5

  5. The diagnosis of Primary/Progressive Multiple Sclerosis
    J Neurol Sci 2003 Feb 15;206(2):145-52

  6. Primary/Progressive Multiple Sclerosis: CerebroSpinal Fluid considerations
    Mult Scler 2004 Jun;10 Suppl 1:S31-4; discussion S34-5

  7. Clinical presentation of Primary/Progressive Multiple Sclerosis 10 years after the incidental finding of typical Magnetic Resonance Imaging Brain lesions: the subclinical stage of Primary/Progressive Multiple Sclerosis may last 10 years
    Mult Scler 2003 Mar;9(2):204-9

  8. Prospective study of patients presenting with acute partial Transverse Myelopathy
    J Neurol 2003 Dec;250(12):1447-52




#1

Primary/Progressive Multiple Sclerosis: Clinical And Paraclinical Characteristics With Application Of The New Diagnostic Criteria

Dujmovic I, Mesaros S, Pekmezovic T, Levic Z, Drulovic J
Eur J Neurol 2004 Jul;11(7):439-44
University of Belgrade, School of Medicine, Institute of Neurology, Dr Subotica, Belgrade, Yugoslavia
PMID# 15257680
Abstract

The aim of our study was to analyse clinical and paraclinical characteristics of patients with Multiple Sclerosis (MS) with previous diagnosis of Primary/Progressive (PP) MS.

According to the Poser's Criteria and further investigate if they fulfil the McDonald's diagnostic criteria for this disorder.

A total of 561 MS patients were registered in the database at the Institute of Neurology, Belgrade, from 1 January 1997 to 31 December 2000 and 63 of them (11.2%) with previous diagnosis of PPMS were analyzed retrospectively.

Male/female ratio was 1.3:1 and mean age at onset 33.2 years.

Most frequent at onset were Pyramidal (in 73% of patients) and sensory symptoms (in 41% of patients); 74.6% of patients had greater than or equal to nine Brain Magnetic Resonance Imaging (MRI) lesions.

Intrathecal OligoClonal ImmunoGlobulin G (IgG) was detected in 96.7% and prolonged Visual Evoked Potentials (VEP) P100 latency in 82.4% of patients.

Of the total study group of 561 patients, 10.2% fulfilled the recently recommended McDonald's diagnostic criteria for the diagnosis of PPMS.

Our findings further support the significance of the Brain/Spinal Cord MRI, CerebroSpinal Fluid and VEP findings for precise diagnostic assessment in patients with suspected PP form of MS.



#2

Magnetic Resonance Imaging Predictors Of Disability In Primary/Progressive Multiple Sclerosis: A 5-Year Study

Stevenson VL, Ingle GT, Miller DH, Thompson AJ
Mult Scler 2004 Aug;10(4):398-401
The National Hospital for Neurology and NeuroSurgery, Department of Clinical Neurology, Queen Square, London WC1N 3BG, UK
PMID# 15327036
Abstract

Magnetic Resonance Imaging (MRI) has become an accepted tool for monitoring therapeutic trials in Relapsing/Remitting and Secondary/Progressive Multiple Sclerosis (MS).

It is however unclear whether such MRI markers are equally applicable to Primary/Progressive MS (PPMS).

Forty-two patients with PPMS were reviewed five years after commencing a two-year MRI and clinical study.

Clinical measures recorded at baseline and five years included both the Expanded Disability Status Scale and the MS Functional Composite.

MRI data collected at baseline and two years included T1 and T2 lesion loads, the number of new Brain and Cord lesions, and measures of both Brain and Cord atrophy.

The study demonstrated that both the number of new T2 lesions and rate of increase in Ventricular volume over two years were modestly predictive of subsequent disease progression and therefore may be useful tools in the testing of new therapeutic agents in PPMS.



#3

Overview Of Primary/Progressive Multiple Sclerosis (PPMS): Similarities And Differences From Other Forms Of MS, Diagnostic Criteria, Pros And Cons Of Progressive Diagnosis

Thompson A
Mult Scler 2004 Jun;10 Suppl 1:S2-7
Institute of Neurology, Department of Clinical Neurology, Queen Square, London WC1N 3BG, UK
PMID# 15218803
Abstract

Patients with the Primary/Progressive form of Multiple Sclerosis (PPMS) have a unique clinical course and demonstrate additional demographic and imaging features, which separate them from the Relapsing/Remitting form of the condition.

Whether these features indicate a fundamental difference in the underlying pathogenesis of the condition or simply reflect opposite ends of a clinical spectrum is unclear.

What is clear, however, is that this form of MS provides a valuable model of progression, which has the potential to explain this most disabling component of the disease process.

The lack of the hallmark relapses and remissions in PPMS poses diagnostic difficulties, some of which have been addressed by recently published diagnostic criteria.

Following diagnosis, the need for information, specific to this form of MS, must be recognized and addressed.



#4

Natural History Of Primary/Progressive Multiple Sclerosis

Ebers GC
Mult Scler 2004 Jun;10 Suppl 1:S8-13; discussion S13-5
Radcliffe Infirmary, University of Oxford, Department of Clinical Neurology, Woodstock Road, Oxford OX2 6HE, UK
PMID# 15218804
Abstract

The relationship of Primary/Progressive Multiple Sclerosis (PPMS) to Relapsing/Remitting MS (RRMS) and Secondary/Progressive MS (SPMS) remains unclear.

Natural history data from a population-based cohort of patients with PPMS followed for approximately 25 years demonstrate remarkable similarities in the progressive phases of PPMS and SPMS.

ImmunoGenetic and Magnetic Resonance Imaging studies in large numbers of patients also fail to differentiate between the two MS categories.

PPMS thus resembles SPMS without the relapses, although the two forms do differ with respect to sex ratio.

An unfavorable outcome in PPMS in predicted by rapid early progression of disability and involvement of three or more systems.

Natural history studies provide information on likely long-term outcomes and can be used in the design and interpretation of clinical trials in PPMS. The evidence that PPMS is distinct remains weak.



#5

The Diagnosis Of Primary/Progressive Multiple Sclerosis

Wolinsky JS; PROMiSe Study Group
J Neurol Sci 2003 Feb 15;206(2):145-52
The University of Texas Health Science Center at Houston, Department of Neurology, 6431 Fannin Street, Houston, TX 77030, USA
PMID# 12559502
Abstract

Primary/Progressive Multiple Sclerosis (PPMS) is a rather unique form of the more common Relapsing Inflammatory DeMyelinative Disease.

The absence of attacks that typify Relapsing forms of MS imposes special challenges for diagnosis.

But, also provides an opportunity to study the pathogenesis of the more Progressive aspects of the disease process in isolation of confounding transient clinical events.

In this review, recent advances in diagnostic approaches are considered in relationship to baseline data from a large multinational study designed to better characterize and treat this clinical phenotype.

PPMS subjects with CerebralSpinal Fluid (CSF) findings consistent with Intrathecal ImmunoGlobulin production may have a more tissue destructive disease process than those whose CSF lacks evidence of a B-Cell ImmunoPathogenic Disease component.



#6

Primary/Progressive Multiple Sclerosis: CerebroSpinal Fluid Considerations

Freedman MS
Mult Scler 2004 Jun;10 Suppl 1:S31-4; discussion S34-5
University of Ottawa, Ottawa Hospital General Campus, Department of Medicine (Neurology), 501 Smith Road, Box 601, Ottawa, Ontario K1H 8L6, Canada
PMID# 15218807
Abstract

Diagnosing the 'Primary/Progressive' form of Multiple Sclerosis (PPMS) requires assurance that other conditions that might cause a chronic Inflammatory NeuroDegenerative Central Nervous System (CNS) Disease have been ruled out.

Both imaging and pathological studies have shown that this form of MS tends to be less inflammatory compared with either the Relapsing/Remitting or Secondary/Progressive types.

There are therefore many conditions that cause a slowly progressive wasting of the CNS that might be confused with MS.

The new MS diagnostic scheme has made the presence of 'typical' MS abnormalities in the CerebroSpinal Fluid (CSF) a mandatory first criterion.

But, there may well be individuals that still have PPMS even in the absence of a typical MS CSF.

Here we explore what the CSF can tell about an individual's disease process and outline the current state of the art in terms of CSF analysis. Used properly, the CSF can be very helpful in clarifying a diagnosis of PPMS.



#7

Clinical Presentation Of Primary/Progressive Multiple Sclerosis 10 Years After The Incidental Finding Of Typical Magnetic Resonance Imaging Brain Lesions: The SubClinical Stage Of Primary/Progressive Multiple Sclerosis May Last 10 Years

McDonnell GV, Cabrera-Gomez J, Calne DB, Li DK, Oger J
Mult Scler 2003 Mar;9(2):204-9
Vancouver Hospital & Health Sciences Centre at UBC Hospital, Multiple Sclerosis Clinic, Vancouver, BC, Canada
PMID# 12708816
Abstract

Background
SubClinical Multiple Sclerosis (MS) has been identified incidentally at autopsy; apparently unaffected individuals with an affected twin have demonstrated Magnetic Resonance Imaging (MRI) changes consistent with MS, and 'MRI relapses' are several times more common than clinical relapses.

Case Description
A 39-year-old, right-handed man underwent MRI and PET scanning in 1986 as a 'normal' control in a Parkinson's Disease study, where his father was the proband.

MRI indicated multiple areas of abnormal signal intensity in a PeriVentricular and Gray-White Matter junction distribution.

Repeated clinical evaluations over the next 10 years were unchanged until 1996, when he complained of progressive weakness of the right foot and clumsiness in the right hand.

MRI now indicated a further area of high signal intensity in the right posterior Cord at the level of C5/C6.

There was mild Pyramidal distribution weakness in the right leg with an Extensor Plantar response on the same side.

Over the next five years there has been mild progression in Weakness and Fatigue and intermittent Lhermitte's Phenomenon.

At no stage has there been a history of relapse, CerebroSpinal Fluid examination was normal and Evoked Responses (Visual and SomatoSensory) are normal.

Conclusion
This case demonstrates the phenomenon of SubClinical MS, unusually supported by prolonged clinical and MRI follow-up.

The patient eventually became symptomatic nine years after MRI diagnosis and is following a Primary/Progressive course.

Although MRI is known to be sensitive in identifying subclinical 'attacks', the pattern illustrated here may actually be quite typical of Primary/Progressive MS and is compatible with the later onset seen in this subgroup of patients.



#8

Prospective Study Of Patients Presenting With Acute Partial Transverse Myelopathy

Cordonnier C, de Seze J, Breteau G, Ferriby D, Michelin E, Stojkovic T, Pruvo JP, Vermersch P
J Neurol 2003 Dec;250(12):1447-52
CHRU de Lille, Dept. of Neurology, Lille, France
PMID# 14673577
Abstract

Background
The clinical and radiological characteristics of Myelopathy in Multiple Sclerosis (MS) are relatively well known.

Nevertheless, it remains difficult for the clinician to ascertain conversion to MS after a first episode of Acute Partial Transverse Myelopathy (APTM).

Objective
The aims of this study were to define predictive factors for conversion to Clinically Definite MS after an APTM and to define predictive factors for disease severity.

Patients And Methods
Between 1994 and 2001, we prospectively included 55 patients presenting with a first episode of APTM. Three patients were lost during the follow-up.

We evaluated clinical signs, Spinal Cord and Brain MRI, CerebroSpinal Fluid (CSF) and Visual Evoked Potentials on admission.

After a mean followup of 35 months (range 12-86), we evaluated the diagnosis and, among the MS group, the severity of the disease.

Results
Of the 52 APTM patients who completed the study, 30 became Clinically Definite MS.

The predictive factors for conversion to MS were: initial Sensory Symptoms, Latero-Posterior Spinal Cord lesion, abnormal Brain MRI and OligoClonal Bands in CSF.

In the MS group, the number of Spinal Cord lesions on MRI was the only predictive factor for a poor outcome, being statistically correlated with a higher number of relapses.

Conclusion
On the basis of our results, we propose that, in patients with APTM, Sensory Symptoms, OligoClonal Bands and Brain MRI are predictive factors.

For subsequent conversion to Clinically Definite MS and that within the latter patients the number of Spinal Cord lesions on MRI is the only predictive factor for a poor outcome.



Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology


MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index


Abstracts
ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses



Copyright 1997 - 2010:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.